Table 4.
Associations between HLA and Graves’ disease in Caucasian population.
| First author | Ref. | Year | Population | Method | No of GD patients | No of controls | Risk antigens/ Alleles |
Protective antigens/ alleles |
|---|---|---|---|---|---|---|---|---|
| Bech K | (63) | 1977 | Danish | serological | 86 | 1967 | B8 Dw3 (both in patients with GD relapse only) |
NR |
| Farid NR | (64) | 1979 | Canadian | serological | 41 | 50 | DRw3 B8 DRw2 |
NR |
| McGregor A | (65) | 1980 | British | serological | 65 | 325 | DRw3 | NR |
| Farid NR | (66) | 1980 | Canadian | serological | 175 | 222 | DRw3 B8 |
NR |
| Allannic H | (67) | 1980 | French | serological | 86 | 100 | DRw3 B8 A1 |
B12 |
| Dahlberg PA | (68) | 1981 | Swedish | serological | 78 | 100 | DR3 B8 |
NR |
| McKenna R | (69) | 1982 | Irish | serological | 86 | 95 | DR3 B8 |
NR |
| Allanic H | (70) | 1983 | French | serological | 72 | 113 | DR3 B8 |
NR |
| Stenszky V | (71) | 1986 | Hungarian | serological | 196 | 380 | A1 DR3 B8 |
NR |
| Kendall-Taylor P | (72) | 1988 | British | serological | 127 | 500 | B8 DR3 |
B17 |
| Semana G | (73) | 1990 | French | Serological RFLP |
287 42 |
200 42 |
DR3 B8 Dw24 |
NR |
| Mangklabruks A | (74) | 1991 | American | RFLP | 65 | 65 | DR3 DQw2 |
NR |
| Schifferdecker E | (75) | 1991 | German | serological | 110 | 193 | B8 Cw7 DR3 |
NR |
| Boehm BO | (80) | 1992 | German | SSOP | 304 | 3724 | DRB3*01:01 | DRB3*02:02 |
| Yanagawa T | (77) | 1993 | American | SSOP | 94 | 75 | DQA1*05:01 | NR |
| Ratanachaiyavong S | (81) | 1994 | British | SSOP | 51 | 166 | Haplotype: HLA-DR17/DQ2, DPB1*01:01 |
NR |
| Badenhoop K | (82) | 1995 | German | SSOP | 271 | 271 | DQA1*0501 | DQB1*0602 |
| Barlow AB | (29) | 1996 | British | SSOP | 127 | 57 | DQA1*05:01 | NR |
| Cuddihy RM | (83) | 1996 | American | SSOP | 101 | 117 | independent significance of DQA1*05:01 not confirmed | NR |
| Kontopoulos A | (84) | 1996 | Greek | SSOP | 105 | 170 |
B*39
DRB1*16:01 |
DRB1*14:01
DQA1*01:04 |
| Lavard L | (85) | 1997 | Danish | SSOP | 90 children |
192 | DRB1*03:01 DQA1*05:01 |
DRB1*07:01
DQA1*02:01 |
| Heward JA | (6) | 1998 | British/Irish | PCR-SSP | 228 | 364 |
DRB1*03:04
DQB1*02 DQB1*03:01 DQB1*03:04 DQA1*05:01 |
NR |
| Chen QY | (86) | 1999 | American | SSP | 92 | 192 |
DRB3*02:02
DRB3*01:01 (early onset) DRB3*02:02 (later onset) |
DRB1*07 |
| Zamani M | (30) | 2000 | Belgian | SSOP | 101 | 205 | DRB1*03:01 DQA1*05:01 |
DRB1*07:01
DQA1*02:01 |
| Ban Y | (87) | 2002 | American | RFLP | 60 | 135 | DR3 | NR |
| Simmonds MJ | (88) | 2005 | British | SSP | 871 | 621 | Haplotype DRB1*03-DQB1*02-DQA1*05:01 DRB1*08 |
Haplotype: DRB1*07- DQB1*02- DQA1*0201 |
| Simmonds MJ | (89) | 2007 | British | SSP | 773 | 621 |
B*08
C*07 |
B*44
C*16 C*03 |
| Bernecker C | (90) | 2013 | Ferman | Flow cytometry | 75 | 60 | none | A2 |
| Martin S | (91) | 2014 | Romanian | SSOP and SSP | 77 | 445 | DRB1*03 DRB1*11 |
DRB1*01
DRB1*15 |
| Vita R | (5) | 2017 | Italian | Serological PCR-SSO |
58 20/58 |
130 | B8, Cw7, DR3, DR4, DQ2 C*07 C*17 DRB1*04 |
B14 |
| Zawadzka-Starczewska K | (13) | 2022 | Polish | NGS | 159 | 2217 |
B*08:01
B*39:06 B*37:01 C*07:01 C*14:02 C*03:02 C*17:01 DRB1*03:01 DRB1*11:01 DRB1*13:03 DRB1*01:03 DRB1*14:01 DQB1*03:01 DQB1*02:01 |
B*07:02, C*07:02 C*03:04 DRB1*07:01 DQB1*02:02 DQB1*03:03 |
NR, not reported; RFLP, restriction fragment length polymorphism; SBT, sequence based typing; SSOP, sequence specific oligonucleotide probe; SSP, sequence specific primers; NGS, next generation sequencing.